{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:53:05Z","timestamp":1787158385606,"version":"build-2736575974"},"reference-count":183,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.apsb.2022.01.012","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T12:21:42Z","timestamp":1642767702000},"page":"2150-2170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Drug discovery of sclerostin inhibitors"],"prefix":"10.1016","volume":"12","author":[{"given":"Sifan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaijian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2197-0439","authenticated-orcid":false,"given":"Meiheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3931-3667","authenticated-orcid":false,"given":"Huan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongkang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Tin Yui","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.01.012_bib1","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/302416","article-title":"Localization of the gene for sclerosteosis to the van Buchem disease\u2013gene region on chromosome 17q12\u2013q21","volume":"64","author":"Balemans","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.apsb.2022.01.012_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/00016925509170789","article-title":"An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris","volume":"44","author":"Van Buchem","year":"1995","journal-title":"Acta Radiol"},{"key":"10.1016\/j.apsb.2022.01.012_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1302\/0301-620X.40B2.208","article-title":"Osteopetrosis with syndactyly","volume":"40","author":"Truswell","year":"1958","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.apsb.2022.01.012_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/en.2017-00794","article-title":"Sclerostin antibody reverses bone loss by increasing bone formation and decreasing bone resorption in a rat model of male osteoporosis","volume":"159","author":"Li","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2022.01.012_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2106\/JBJS.G.01183","article-title":"Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling","volume":"90 Suppl 1","author":"ten Dijke","year":"2008","journal-title":"JBJS"},{"key":"10.1016\/j.apsb.2022.01.012_bib6","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","article-title":"Romosozumab: a first-in-class sclerostin inhibitor for osteoporosis","volume":"77","author":"Prather","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.apsb.2022.01.012_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1210\/TEAM.9781879225718.ch2","article-title":"Pathogenesis of osteoporosis","volume":"1","author":"Khosla","year":"2010","journal-title":"Transl Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.012_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jbmr.4197","article-title":"Clinical phenotype and relevance of LRP5 and LRP6 variants in patients with early-onset osteoporosis (EOOP)","volume":"36","author":"St\u00fcrznickel","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib9","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.1158\/0008-5472.CAN-05-1891","article-title":"Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism","volume":"65","author":"Dai","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib10","doi-asserted-by":"crossref","first-page":"E2584","DOI":"10.1210\/jc.2013-4493","article-title":"Circulating sclerostin associated with vertebral bone marrow fat in older men but not women","volume":"99","author":"Ma","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.012_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/cen.12364","article-title":"Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus","volume":"80","author":"Neumann","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib12","doi-asserted-by":"crossref","first-page":"115053","DOI":"10.1016\/j.bone.2019.115053","article-title":"Association\u00a0of serum sclerostin levels with low skeletal muscle mass: the Korean Sarcopenic Obesity Study (KSOS)","volume":"128","author":"Kim","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib13","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.3390\/ijms21093199","article-title":"The role of sclerostin in bone and ectopic calcification","volume":"21","author":"De Mar\u00e9","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.01.012_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.201006123","article-title":"The two faces of serotonin in bone biology","volume":"191","author":"Ducy","year":"2020","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib15","doi-asserted-by":"crossref","first-page":"10890","DOI":"10.1074\/jbc.M807994200","article-title":"Characterization of the structural features and interactions of sclerostin","volume":"284","author":"Veverka","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib16","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1038\/s41467-020-19155-4","article-title":"Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.01.012_bib17","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2022.01.012_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0765.2009.01227.x","article-title":"Localization of SOST\/sclerostin in cementocytes in\u00a0vivo and in mineralizing periodontal ligament cells in\u00a0vitro","volume":"45","author":"J\u00e4ger","year":"2010","journal-title":"J Periodont Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.str.2011.07.005","article-title":"Wnt antagonists bind through a short peptide to the first \u03b2-propeller domain of LRP5\/6","volume":"19","author":"Bourhis","year":"2011","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2022.01.012_bib20","doi-asserted-by":"crossref","first-page":"e81710","DOI":"10.1371\/journal.pone.0081710","article-title":"Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition","volume":"8","author":"Boschert","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.012_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2741\/4214","article-title":"Wnt and the Wnt signaling pathway in bone development and disease","volume":"19","author":"Wang","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.apsb.2022.01.012_bib22","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/me.2007-0259","article-title":"Gone with the Wnts: \u03b2-Catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism","volume":"21","author":"Manolagas","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib23","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1215458","article-title":"WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta","volume":"368","author":"Laine","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib24","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/jbmr.1834","article-title":"\u03b2-Catenin promotes bone formation and suppresses bone resorption in postnatal growing mice","volume":"28","author":"Chen","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib25","doi-asserted-by":"crossref","first-page":"a007880","DOI":"10.1101\/cshperspect.a007880","article-title":"Frizzled and LRP5\/6 receptors for Wnt\/\u03b2-catenin signaling","volume":"4","author":"MacDonald","year":"2012","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib26","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2007.11.036","article-title":"SnapShot: Wnt\/\u03b2-catenin signaling","volume":"131","author":"MacDonald","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2022.01.012_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nsmb912","article-title":"\u03b2-Catenin directly displaces Groucho\/TLE repressors from Tcf\/Lef in Wnt-mediated transcription activation","volume":"12","author":"Daniels","year":"2005","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib28","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1021\/jf904158k","article-title":"Betulinic acid stimulates the differentiation and mineralization of osteoblastic MC3T3-E1 cells: involvement of BMP\/Runx2 and \u03b2-catenin signals","volume":"58","author":"Lo","year":"2010","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bone.2015.02.009","article-title":"Wnt signaling in bone and muscle","volume":"80","author":"Rudnicki","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib31","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1530\/JME-18-0176","article-title":"Novel actions of sclerostin on bone","volume":"62","author":"Holdsworth","year":"2019","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib32","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1210\/jc.2013-3278","article-title":"Serum Dickkopf 1 levels in sclerostin deficiency","volume":"99","author":"Van Lierop","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.012_bib33","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98673","article-title":"Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition","volume":"3","author":"Witcher","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2022.01.012_bib34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00223-018-0420-6","article-title":"Dkk1 KO mice treated with sclerostin antibody have additional increases in bone volume","volume":"103","author":"Morse","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib35","doi-asserted-by":"crossref","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-\u03baB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib36","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2022.01.012_bib37","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1172\/JCI38716","article-title":"NF-\u03baB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism","volume":"119","author":"Yao","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.012_bib38","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3390\/ijms18071432","article-title":"Polymorphisms within genes involved in regulation of the NF-\u03baB pathway in patients with rheumatoid arthritis","volume":"18","author":"G\u0119bura","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2022.01.012_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni.2065","article-title":"Crosstalk in NF-\u03baB signaling pathways","volume":"12","author":"Oeckinghaus","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2022.01.012_bib40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fimmu.2016.00378","article-title":"Crosstalk between Wnt\/\u03b2-catenin and NF-\u03baB signaling pathway during inflammation","volume":"7","author":"Ma","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2022.01.012_bib41","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/art.34425","article-title":"A Wnt\/\u03b2-catenin negative feedback loop inhibits interleukin-1-induced matrix metalloproteinase expression in human articular chondrocytes","volume":"64","author":"Ma","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.apsb.2022.01.012_bib42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molimm.2012.04.005","article-title":"Glycogen synthase kinase-3 beta inhibitor suppresses Porphyromonas gingivalis lipopolysaccharide-induced CD40 expression by inhibiting nuclear factor-kappa B activation in mouse osteoblasts","volume":"52","author":"Die","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2022.01.012_bib43","doi-asserted-by":"crossref","first-page":"22424","DOI":"10.1002\/jcp.28807","article-title":"Targeting MAPKs, NF-\u03baB, and PI3K\/AKT pathways by methyl palmitate ameliorates ethanol-induced gastric mucosal injury in rats","volume":"234","author":"Arab","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2022.01.012_bib44","doi-asserted-by":"crossref","first-page":"330ra35","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fcell.2020.00325","article-title":"Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s11657-014-0182-3","article-title":"Estimating prevalence of osteoporosis: examples from industrialized countries","volume":"9","author":"Wade","year":"2014","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.apsb.2022.01.012_bib47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jbmr.2342","article-title":"Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women","volume":"30","author":"Reppe","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib49","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib50","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.012_bib51","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib52","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-021-00836-1","article-title":"Disuse osteoporosis: clinical and mechanistic insights","volume":"110","author":"Rolvien","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11914-013-0136-5","article-title":"Spaceflight-induced bone loss: is there an osteoporosis risk?.","volume":"11","author":"Sibonga","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.apsb.2022.01.012_bib54","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.090411","article-title":"Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/\u03b2-catenin signaling","volume":"24","author":"Lin","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib55","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in\u00a0vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2016.12.003","article-title":"Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats","volume":"97","author":"Ma","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib57","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jbmr.4193","article-title":"Mechanically driven counter-regulation of cortical bone formation in response to sclerostin-neutralizing antibodies","volume":"36","author":"Gerbaix","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib58","first-page":"869","article-title":"Evaluation of cardiovascular risks of spaceflight does not support the NASA bioastronautics critical path roadmap","volume":"76","author":"Convertino","year":"2005","journal-title":"Aviat Space Environ Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/srep29901","article-title":"Apollo lunar astronauts show higher cardiovascular disease mortality: possible deep space radiation effects on the vascular endothelium","volume":"6","author":"Delp","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.01.012_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bone.2014.10.018","article-title":"Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength","volume":"71","author":"Morse","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib61","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s11999-015-4640-z","article-title":"Does sclerostin depletion stimulate fracture healing in a mouse model?.","volume":"474","author":"Alzahrani","year":"2016","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib62","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jbmr.307","article-title":"Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones","volume":"26","author":"Ominsky","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2015.04.048","article-title":"Sclerostin antibody treatment improves fracture outcomes in a type I diabetic mouse model","volume":"82","author":"Yee","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00223-017-0275-2","article-title":"Sclerostin antibody increases callus size and strength but does not improve fracture union in a challenged open rat fracture model","volume":"101","author":"Morse","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib65","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/jbmr.3454","article-title":"Sclerostin neutralizing antibody treatment enhances bone formation but does not rescue mechanically induced delayed healing","volume":"33","author":"Kruck","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib66","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/jbmr.135","article-title":"Sclerostin antibody treatment enhances metaphyseal bone healing in rats","volume":"25","author":"Agholme","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib67","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.01.012_bib68","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2106\/JBJS.19.01008","article-title":"Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study","volume":"102","author":"Bhandari","year":"2020","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.apsb.2022.01.012_bib69","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures","volume":"102","author":"Schemitsch","year":"2020","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.apsb.2022.01.012_bib70","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s40520-019-01399-w","article-title":"Osteosarcopenia among postmenopausal women and handgrip strength as a practical method for predicting the risk","volume":"32","author":"Hamad","year":"2020","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib71","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fendo.2019.00924","article-title":"Management of osteogenesis imperfecta","volume":"10","author":"Ralston","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib72","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib73","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/jbmr.3858","article-title":"Sclerostin antibody-induced changes in bone mass are site specific in developing crania","volume":"34","author":"Scheiber","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib74","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.diff.2012.04.001","article-title":"Atrioventricular valve development: new perspectives on an old theme","volume":"84","author":"de Vlaming","year":"2012","journal-title":"Differentiation"},{"key":"10.1016\/j.apsb.2022.01.012_bib76","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2022.01.012_bib77","first-page":"722","article-title":"Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia","volume":"118","author":"Yuan","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.012_bib78","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2022.01.012_bib79","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.01.012_bib80","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.012_bib81","doi-asserted-by":"crossref","first-page":"E920","DOI":"10.1210\/jc.2013-3852","article-title":"Circulating sclerostin in children and young adults with heritable bone disorders","volume":"99","author":"Palomo","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.012_bib82","doi-asserted-by":"crossref","first-page":"e97326","DOI":"10.1371\/journal.pone.0097326","article-title":"PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism","volume":"9","author":"Zelenchuk","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.012_bib83","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.1221255110","article-title":"Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium","volume":"110","author":"Ryan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.012_bib84","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbmr.3923","article-title":"Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice","volume":"35","author":"Carpenter","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib85","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Clinical renal pharmacology and therapeutics","volume":"24","author":"Aono","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib86","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2783","article-title":"1,25-Dihydroxyvitamin D alone improves skeletal growth, microarchitecture, and strength in a murine model of XLH, despite enhanced FGF23 expression","volume":"31","author":"Liu","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.01.012_bib88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2017.11.015","article-title":"Sclerostin deficiency modifies the development of CKD\u2013MBD in mice","volume":"107","author":"Kaesler","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib89","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/jbmr.4203","article-title":"Chronic kidney disease-induced vascular calcification impairs bone metabolism","volume":"36","author":"Mace","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib90","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41100-016-0024-4","article-title":"Role of sclerostin in the pathogenesis of chronic kidney disease\u2013mineral bone disorder","volume":"2","author":"Asamiya","year":"2016","journal-title":"Ren Replace Ther"},{"key":"10.1016\/j.apsb.2022.01.012_bib91","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2215\/CJN.07670712","article-title":"The relation between renal function and serum sclerostin in adult patients with CKD","volume":"8","author":"Pelletier","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.apsb.2022.01.012_bib92","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","article-title":"The chronic kidney disease\u2013mineral bone disorder (CKD\u2013MBD): advances in pathophysiology","volume":"100","author":"Hruska","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib93","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00223-007-9004-6","article-title":"Association between systemic calcified atherosclerosis and bone density","volume":"80","author":"Hyder","year":"2007","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib94","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02390833","article-title":"Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study","volume":"68","author":"Kiel","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11255-019-02290-3","article-title":"Sclerostin: a new biomarker of CKD\u2013MBD","volume":"52","author":"Figurek","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.apsb.2022.01.012_bib96","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2022.01.012_bib97","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1038\/s41598-017-11913-7","article-title":"Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2022.01.012_bib98","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125543","article-title":"Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness","volume":"4","author":"Hesse","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2022.01.012_bib99","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1172\/JCI99673","article-title":"\u0394Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer","volume":"128","author":"Kumar","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2022.01.012_bib100","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1084\/jem.20130281","article-title":"Down-regulation of PLC\u03b32\u2013\u03b2-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer","volume":"210","author":"Capietto","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib101","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1158\/0008-5472.CAN-15-0898","article-title":"The CUL4B\/AKT\/\u03b2-catenin axis restricts the accumulation of myeloid-derived suppressor cells to prohibit the establishment of a tumor-permissive microenvironment","volume":"75","author":"Qian","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib102","first-page":"164","article-title":"The roles of sclerostin in immune system and the applications of aptamers in immune-related research","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2022.01.012_bib103","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1074248418770623","article-title":"Effects of enoxaparin on intravascular sclerostin release in healthy men","volume":"23","author":"Borawski","year":"2018","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.apsb.2022.01.012_bib104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bone.2017.03.001","article-title":"Sclerostin stimulates angiogenesis in human endothelial cells","volume":"101","author":"Oranger","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2265.2011.04315.x","article-title":"Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women","volume":"76","author":"Sheng","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib106","doi-asserted-by":"crossref","first-page":"E1473","DOI":"10.1210\/jc.2012-1218","article-title":"Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women","volume":"97","author":"Urano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2022.01.012_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000497113","article-title":"The bone markers sclerostin, osteoprotegerin, and bone-specific alkaline phosphatase are related to insulin resistance in children and adolescents, independent of their association with growth and obesity","volume":"91","author":"Stanik","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.apsb.2022.01.012_bib108","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/jcp.24487","article-title":"TNF-\u03b1 upregulates sclerostin expression in obese mice fed a high-fat diet","volume":"229","author":"Baek","year":"2014","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2022.01.012_bib109","doi-asserted-by":"crossref","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","article-title":"Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes","volume":"114","author":"Kim","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2022.01.012_bib110","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jcb.25432","article-title":"Sclerostin enhances adipocyte differentiation in 3T3-L1 cells","volume":"117","author":"Ukita","year":"2016","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2022.01.012_bib111","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.3001","article-title":"Osteocyte-secreted Wnt signaling inhibitor sclerostin contributes to beige adipogenesis in peripheral fat depots","volume":"32","author":"Fulzele","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib112","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc14-2989","article-title":"Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism","volume":"38","author":"Daniele","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.apsb.2022.01.012_bib113","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1479164113510923","article-title":"The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus","volume":"11","author":"Gaudio","year":"2014","journal-title":"Diabets Vasc Dis Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib114","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrcardio.2010.209","article-title":"Impact of obesity on total and cardiovascular mortality-fat or fiction?.","volume":"8","author":"Cepeda-Valery","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2022.01.012_bib115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5312\/wjo.v5.i3.247","article-title":"Bone anabolics in osteoporosis: actuality and perspectives","volume":"5","author":"Montagnani","year":"2014","journal-title":"World J Orthop"},{"key":"10.1016\/j.apsb.2022.01.012_bib116","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2015.01.010","article-title":"Association of circulating sclerostin with vascular calcification in Afro-Caribbean men","volume":"239","author":"Kuipers","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2022.01.012_bib117","first-page":"317","article-title":"Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study","volume":"22","author":"Koos","year":"2013","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.apsb.2022.01.012_bib118","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/scitranslmed.aay6570","article-title":"Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics","volume":"12","author":"Bovijn","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib119","first-page":"745","article-title":"The relationship among serum sclerostin, coronary atherosclerotic heart disease, and osteoporosis in the elderly","volume":"23","author":"He","year":"2017","journal-title":"Chin J Osteoporosis"},{"key":"10.1016\/j.apsb.2022.01.012_bib120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12872-018-0955-5","article-title":"Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients","volume":"18","author":"Chang","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.apsb.2022.01.012_bib121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.metabol.2017.10.005","article-title":"Genetics of Sost\/SOST in sclerosteosis and van Buchem disease animal models","volume":"80","author":"Sebastian","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.apsb.2022.01.012_bib122","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/jbmr.1807","article-title":"Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading","volume":"28","author":"Spatz","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib123","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib124","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2016.02.005","article-title":"Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse","volume":"87","author":"Zhang","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jbmr.2396","article-title":"Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss","volume":"30","author":"Beggs","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib126","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib127","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.apsb.2022.01.012_bib128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","article-title":"Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/jbmr.2996","article-title":"Suppression of sclerostin alleviates radiation-induced bone loss by protecting bone-forming cells and their progenitors through distinct mechanisms","volume":"32","author":"Chandra","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.matbio.2015.12.009","article-title":"Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1 (Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23","volume":"52","author":"Ren","year":"2016","journal-title":"Matrix Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib131","doi-asserted-by":"crossref","first-page":"e62295","DOI":"10.1371\/journal.pone.0062295","article-title":"Anti-sclerostin antibody inhibits internalization of sclerostin and sclerostin-mediated antagonism of Wnt\/LRP6 signaling","volume":"8","author":"van Dinther","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2022.01.012_bib132","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib133","doi-asserted-by":"crossref","first-page":"6217286","DOI":"10.1155\/2016\/6217286","article-title":"Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges","volume":"2016","author":"MacNabb","year":"2016","journal-title":"J Osteoporos"},{"key":"10.1016\/j.apsb.2022.01.012_bib134","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jpha.2020.08.005","article-title":"Liquid chromatography\u2013mass spectrometry method for the quantification of an anti-sclerostin monoclonal antibody in cynomolgus monkey serum","volume":"11","author":"Gao","year":"2021","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.apsb.2022.01.012_bib135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib136","doi-asserted-by":"crossref","first-page":"160120","DOI":"10.1098\/rsob.160120","article-title":"The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6","volume":"6","author":"Boschert","year":"2016","journal-title":"Open Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib137","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14656566.2019.1594772","article-title":"Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss","volume":"20","author":"Fontalis","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.apsb.2022.01.012_bib138","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib139","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.4155\/bio-2017-0289","article-title":"A bridging immunogenicity assay for monoclonal antibody: case study with SHR-1222","volume":"10","author":"Zhang","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.apsb.2022.01.012_bib140","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMe1711298","article-title":"Romosozumab-promising or practice changing","volume":"377","author":"Rosen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.01.012_bib141","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.15586\/jptcp.v27i1.655","article-title":"Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: a review","volume":"27","author":"Shakeri","year":"2020","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.012_bib142","first-page":"565","article-title":"Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis","volume":"7","author":"Shah","year":"2015","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.apsb.2022.01.012_bib143","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Sem\u00ebnov","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib144","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrendo.2013.154","article-title":"Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches","volume":"9","author":"Canalis","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/164_2020_373","article-title":"Osteoporosis therapeutics 2020","volume":"262","author":"Kocijan","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.012_bib146","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib147","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.01.012_bib148","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","article-title":"Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study","volume":"14","author":"Brandenburg","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.apsb.2022.01.012_bib149","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/jbmr.4001","article-title":"Serious adverse events with romosozumab use in Japanese patients: need for clear formulation of contraindications worldwide","volume":"35","author":"Kawaguchi","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib150","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.apsb.2022.01.012_bib151","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.apsb.2022.01.012_bib152","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.nwh.2019.11.002","article-title":"New osteoporosis treatment means new bone formation","volume":"24","author":"Blakely","year":"2020","journal-title":"Nurs Womens Health"},{"key":"10.1016\/j.apsb.2022.01.012_bib153","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.01.012_bib154","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/BJ20101096","article-title":"Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling","volume":"434","author":"Shum","year":"2011","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2022.01.012_bib155","series-title":"American Society of Bone and Mineral Research 2020 annual meeting","first-page":"657","article-title":"Poster: Sclerostin loop3: a potential target for developing a next generation sclerostin inhibitor for bone anabolic therapy with low cardiovascular concern","author":"Yu","year":"2020"},{"key":"10.1016\/j.apsb.2022.01.012_bib156","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","article-title":"Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis","volume":"37","author":"Krishna","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib157","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2022.01.012_bib158","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.01.012_bib159","doi-asserted-by":"crossref","first-page":"1903451","DOI":"10.1002\/advs.201903451","article-title":"A loop-based and AGO-incorporated virtual screening model targeting AGO-mediated miRNA\u2013mRNA interactions for drug discovery to rescue bone phenotype in genetically modified mice","volume":"7","author":"Zhuo","year":"2020","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2022.01.012_bib160","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2022.01.012_bib161","doi-asserted-by":"crossref","first-page":"871","DOI":"10.33549\/physiolres.933267","article-title":"Identification of novel small molecules that bind to the Loop2 region of sclerostin\u2014an in silico computational analysis","volume":"65","author":"Muthusamy","year":"2016","journal-title":"Physiol Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib162","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1080\/07391102.2019.1599427","article-title":"Discovery of potential sclerostin inhibitors from plants with loop2 region of sclerostin inhibition by interacting with residues outside Pro-Asn-Ala-Ile-Gly motif","volume":"38","author":"Yooin","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.apsb.2022.01.012_bib163","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.1021\/acs.jmedchem.9b00179","article-title":"Hydroxyl groups in synthetic and natural-product-derived therapeutics: a perspective on a common functional group","volume":"62","author":"Cramer","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib164","doi-asserted-by":"crossref","first-page":"26464","DOI":"10.1074\/jbc.M112.350108","article-title":"Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors","volume":"287","author":"Holdsworth","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1759720X12466608","article-title":"Wnt signaling in bone formation and its therapeutic potential for bone diseases","volume":"5","author":"Kim","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.apsb.2022.01.012_bib166","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bmcl.2018.01.050","article-title":"In silico discovery of quinoxaline derivatives as novel LRP5\/6\u2013sclerostin interaction inhibitors","volume":"28","author":"Choi","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2022.01.012_bib167","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10593-012-0960-z","article-title":"Heterocycles in drugs and drug discovery","volume":"48","author":"Gomtsyan","year":"2020","journal-title":"Chem Heterocycl Compd"},{"key":"10.1016\/j.apsb.2022.01.012_bib168","doi-asserted-by":"crossref","first-page":"895","DOI":"10.6023\/A18060228","article-title":"Efficient and facile synthesis of chiral sulfonamides via asymmetric multicomponent reactions","volume":"76","author":"Yu","year":"2018","journal-title":"Acta Chim Sin"},{"key":"10.1016\/j.apsb.2022.01.012_bib169","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1021\/acs.jmedchem.0c00754","article-title":"The most common functional groups in bioactive molecules and how their popularity has evolved over time","volume":"63","author":"Ertl","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib170","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s40520-019-01393-2","article-title":"Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention","volume":"32","author":"He","year":"2020","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.apsb.2022.01.012_bib171","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/jphp.12607","article-title":"Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities","volume":"68","author":"Wong","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2022.01.012_bib172","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2017.03.015","article-title":"Novel strategies in the oral delivery of antidiabetic peptide drugs\u2014insulin, GLP 1 and its analogs","volume":"115","author":"Ismail","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2022.01.012_bib173","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/ph11020042","article-title":"2017 FDA peptide harvest","volume":"11","author":"Al Musaimi","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2022.01.012_bib174","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-019-1902-z","article-title":"Activation of the GLP-1 receptor by a non-peptidic agonist","volume":"577","author":"Zhao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.01.012_bib175","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.apsb.2022.01.012_bib176","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1161\/ATVBAHA.119.312371","article-title":"Cardiovascular outcomes of romosozumab and protective role of alendronate","volume":"39","author":"Asadipooya","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib177","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2022.01.012_bib178","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cbpa.2007.08.033","article-title":"Virtual screening strategies in drug discovery","volume":"11","author":"McInnes","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.apsb.2022.01.012_bib179","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fchem.2021.662688","article-title":"Applications of virtual screening in\u00a0bioprospecting: facts, shifts, and perspectives to explore the\u00a0chemo-structural diversity of natural products","volume":"9","author":"Santana","year":"2021","journal-title":"Front Chem"},{"key":"10.1016\/j.apsb.2022.01.012_bib180","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1109\/TCBB.2016.2535233","article-title":"Predicting the absorption potential of chemical compounds through a deep learning approach","volume":"15","author":"Shin","year":"2018","journal-title":"IEEE\/ACM Trans Comput Biol Bioinf"},{"key":"10.1016\/j.apsb.2022.01.012_bib181","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fenvs.2015.00080","article-title":"DeepTox: toxicity prediction using deep learning","volume":"3","author":"Mayr","year":"2016","journal-title":"Front Environ Sci"},{"key":"10.1016\/j.apsb.2022.01.012_bib182","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2022.01.012_bib183","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1021\/acsami.0c05750","article-title":"Recent progress in aptamer discoveries and modifications for therapeutic applications","volume":"13","author":"Ni","year":"2021","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:55:43Z","timestamp":1761929743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":183,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2211383522000259"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.01.012","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug discovery of sclerostin inhibitors","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}